Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2021 earnings results today. Total revenues increased 8% year-over-year to $12 billion, driven by Eliquis, Immuno-Oncology and new product portfolios. Net earnings attributable to Bristol Myers Squibb was $2.4 billion, or $1.07 per share, compared to a net loss of $10 billion, or $4.45 per share, in […]
“Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2021 earnings results today. Total revenues increased 8% year-over-year to $12 billion, driven by Eliquis, Immuno-Oncology and new product portfolios. Net earnings attributable to Bristol Myers Squibb was $2.4 billion, or $1.07 per share, compared to a net loss of $10 billion, or $4.45 per share, in […]
· February 4, 2022
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2021 earnings results today.
Total revenues increased 8% year-over-year to $12 billion, driven by Eliquis, Immuno-Oncology and new product portfolios.
Net earnings attributable to Bristol Myers Squibb was $2.4 billion, or $1.07 per share, compared to a net loss of $10 billion, or $4.45 per share, in the same period a year ago. Adjusted net earnings was $4.1 billion, or $1.83 per share.
For the full year of 2022, worldwide revenues are expected to be approx. $47 billion. GAAP EPS is estimated to be $3.37-3.67 while adjusted EPS is estimated to be $7.65-7.95.
